Researchers and physicians at Mumbai's Tata Institute have created a medication that they believe may stop cancer from coming back.
This novel pill is thought to prevent cancer from returning and minimise side effects from treatments like radiation and chemotherapy by 50%. It is the product of 10 years of study and testing. The studies were carried out on mice, a mammal that is closely related to humans genetically.
The study team's leading cancer surgeon at Tata Memorial Hospital, Dr. Rajendra Badve, described how the finding was made.

"For the purpose of the study, rats were given human cancer cells, which developed into tumours in the rats. Following that, the rats received surgery, chemotherapy, and radiation therapy. It was discovered that these cancer cells fragment into microscopic fragments known as chromatin particles upon death. These particles may penetrate healthy cells and spread to other regions of the body through the circulation, where they can cause cancer, according to Dr. Badve, who spoke to NDTV.

To address this issue, the researchers gave the rats pro-oxidant pills that included copper (R+Cu) and resveratrol (R). The chromatin particles are successfully destroyed by the oxygen radicals produced by the R+Cu tablets.
These pills produce oxygen radicals in the stomach upon oral administration, which swiftly reach the circulation. This procedure stops cancer cells from spreading, a process known as metastases, and stops the release of chromatin particles free of cells into the bloodstream.
Additionally, according to the researchers, R+Cu pills lessen the toxicity that comes with treatment.

This finding, known as the "Magic of R+Cu," is predicted to show a 30% efficacy in avoiding cancer recurrence and reducing adverse effects of cancer treatment therapy by around 50%.
It is expected that the pill will work against malignancies of the mouth, lungs, and pancreas.
At now, the physicians are anticipating the endorsement from the Food Safety and Standards Authority of india (FSSAI). The tablet is anticipated to hit stores in june or July after approval.
According to Dr. Badve, if the pill is authorised, its price will be significantly lower. He stated that "compared to the lakhs and crores spent on the development, the tablet could be less than Rs 100."

Rats and humans have both been used to assess the tablet's influence on adverse effects; only rats have been used for preventative studies.
It is anticipated that human trials would take a minimum of five years to conclude. "There were difficulties with the study, and many people thought it was a time and money waste. However, everyone is joyful and enthusiastic today. It is rather successful," he declared.

మరింత సమాచారం తెలుసుకోండి: